Go CAR-Ting and Beyond for Kids: State of the Art of Pediatric Cell-Based Therapies

Moderator(s)

• 

  Shaun Jackson, MD, PhD

  Seattle Children's Research Institute
  Seattle, Washington, United States

  Disclosure(s): Merck/MSD: Consultant (Ongoing)
• HW

  Holly Wobma, MD, PhD

  Boston Children's Hospital
  Boston, Massachusetts, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose

Session Coordinator(s)

• SS

  Susan Shenoi, MBBS, MS, RhMSUS

  Seattle Children's Hospital and Research Center
  Mercer Island, WA, United States

  Disclosure(s): AbbVie/Abbott: Consultant (Terminated); cabaletta: Consultant (Ongoing); sobi: Consultant (Ongoing)
• EO

  Ekemini Ogbu, MD, MSc

  Cincinnati Children's Hospital Medical Center
  Cincinnati, OH, United States

  Disclosure information not submitted.

This session will explore the emergence and potential impact of Chimeric Antigen Receptor (CAR) T-cell therapies in pediatric rheumatic diseases. It will provide a comprehensive overview of recent advancements in the field, with a focus on CAR T-cell therapy research in childhood-onset systemic lupus erythematosus and juvenile dermatomyositis. The session will also address the ethical and practical challenges associated with conducting cell-based therapy research in rare pediatric rheumatic diseases and discuss future opportunities for innovation and development in this area.

Presentations:

• 9:00 AM – 10:00 AM Central Time

  State of the Art: Pediatric Cell-Based Therapies
  

  Speaker: Georg Schett, MD – Friedrich-Alexander-Universität Erlangen-Nürnberg